Showing results (201-210 of 771) with videos related to
Sort By:
Pageof 78
Cutis|May 19, 2009
Calcitriol ointment 3 microg/g is safe and effective over 52 weeks for the treatment of mild to moderate plaque psoriasisMark Lebwohl, Jean-Paul Ortonne, Philippe Andres, et al.Journal of Drugs in Dermatology : JDD|July 2, 2011
A bilateral comparison study of pimecrolimus cream 1% and a topical medical device cream in the treatment of patients with atopic dermatitisJason J Emer, Amylynne Frankel, Andrew Sohn, et al.Journal of Drugs in Dermatology : JDD|July 8, 2025
Tirbanibulin 1% Ointment: Clinical Trial and Real-World Evidence on Efficacy, Tolerability, Safety, and Patient-Reported OutcomesCharlotte Jeong, Leon Kircik, Mark Lebwohl, et al.Dermatology Online Journal|June 16, 2018
Restrictions on blood donations relevant to dermatologyAmir Al-Dabagh, Steven FeldmanJournal of Drugs in Dermatology : JDD|June 3, 2020
Importance of Complete Skin Clearance in Psoriasis as a Treatment Goal: Implications for Patient-Reported OutcomesAndrew Blauvelt, Jashin J Wu, April Armstrong, et al.Journal of Drugs in Dermatology : JDD|October 15, 2016
Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind StudyAlice Gottlieb, Alan Menter, April Armstrong, et al.Journal of the American Academy of Dermatology|April 19, 2014
The spectrum of oculocutaneous disease: Part II. Neoplastic and drug-related causes of oculocutaneous diseaseAntoinette Day, Amanda K Abramson, Mahir Patel, et al.Dermatology and Therapy|August 21, 2020
A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe PsoriasisEmily K Haque, Aaminah Azhar, John Corbett, et al.Drug Safety|July 19, 2008
Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trialTiffani Hamilton, Alan Menter, Ivor Caro, et al.Journal of Drugs in Dermatology : JDD|February 18, 2004
Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasisAlan Menter, Mark Kosinski, Brian W Bresnahan, et al.Pageof 78